FDAnews Drug Daily Bulletin

RP-606 RIGHTS REVERT TO MEDIVIR

Dec. 12, 2005
A A

Medivir announced today that all rights relating to the development of RP-606 (MIV-606), an oral antiviral being developed for the treatment of herpes zoster (shingles) and post-herpetic neuralgia (PHN), the chronic pain which is associated with shingles, have been reverted to Medivir. The reversion is effected by way of a mutual termination of the license agreement with Reliant Pharmaceuticals, Inc., which is now focusing on the marketing and development of its portfolio of cardiovascular products.

PrimeZone (http://www.primezone.com/newsroom/news.html?d=90994)